Savara Inc. SVRA
$5.00
-1.38%
at last close
Market Cap$1.04 billion
P/E Ratio—
Div Yield—
Volume2.45M
52-Week Range
$2.92$7.00
Analyst Ratings
- Consensus
- Buy — 5 Buy · 0 Hold · 0 Sell (5 analysts)
- Avg. Price Target
- $9.80 (+96.0% upside)
Key Stats
- Today's Range
- $4.87 – $5.18
- 50-Day Range
- $4.87 – $6.03
- 52-Week Range
- $2.92 – $7.00
- Volume
- 2.45 million shs
- Average Volume
- 1.61 million shs
- Market Cap
- $1.04 billion
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- -1950.72
- Price / Sales
- —
Short Interest
- Short Interest
- 0.16%
- Days to Cover
- 2.47
Financials (TTM)
- Revenue
- —
- Net Income
- $-139,309,000
- Net Margin
- —
- Return on Equity
- 26087.83%
- Debt-to-Equity
- -56.38
About Savara Inc.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
Related Stocks
Compare head-to-head: SVRA vs LLY·SVRA vs JNJ·SVRA vs ABBV·SVRA vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.